Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 13 unusual trades.
Delving into the details, we found 61% of traders were bullish, while 23% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $495,955, and 6 were calls, valued at $263,160.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $90.0 for Gilead Sciences over the recent three months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Gilead Sciences stands at 1270.25, with a total volume reaching 3,306.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $90.0, throughout the last 30 days.
Gilead Sciences Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | PUT | SWEEP | BULLISH | 01/17/25 | $4.05 | $3.9 | $3.9 | $65.00 | $102.9K | 2.5K | 266 |
| GILD | CALL | SWEEP | BULLISH | 06/20/25 | $4.95 | $4.85 | $4.95 | $72.50 | $95.0K | 122 | 194 |
| GILD | PUT | SWEEP | BEARISH | 11/15/24 | $5.55 | $5.45 | $5.55 | $70.00 | $90.4K | 428 | 172 |
| GILD | PUT | TRADE | BEARISH | 06/20/25 | $2.3 | $2.12 | $2.3 | $55.00 | $75.8K | 1.0K | 332 |
| GILD | PUT | TRADE | BEARISH | 01/17/25 | $1.21 | $1.17 | $1.2 | $55.00 | $63.6K | 2.4K | 530 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Gilead Sciences
- With a volume of 1,845,363, the price of GILD is up 0.09% at $67.71.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 78 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
